data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

My Account

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Freight
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Yield
How to Buy Corporate Bonds
How to Buy Treasury Bonds
How to Invest in Real Estate Online
Money
Compare Online Brokers
Stock Brokers
Forex Brokers
Futures Brokers
Crypto Brokers
Options Brokers
ETF Brokers
Mutual Fund Brokers
Index Fund Brokers
Bond Brokers
Short Selling Brokers
Stock Apps
All Broker Reviews
Insurance
Auto
Home
Medicare
Life
Vision
Dental
Business
Pet
Health
Motorcycle
Renters
Workers Comp
Top Stocks
Penny Stocks
Stocks Under $5
Stocks Under $10
Stocks Under $20
Stocks Under $50
Stocks Under $100
Alternative Investing
Invest in Art
Invest in Watches
Invest in Land
Invest in Real Estate
Invest in Wine
Invest in Gold
Mortgages
Refinance
Purchase
Find a Mortgage Broker
Alts
Alternative Investment Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
How to Invest in Jewelry
Best Real Estate Crowdfunding Platforms
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Get Started
Is Bitcoin a Good Investment?
Is Ethereum a Good Investment?
What is Blockchain
Best Altcoins
How to Buy Cryptocurrency?
DeFi
Crypto and DeFi 101
What is DeFi?
Decentralized Exchanges
Best DeFi Yield Farms
Digital Securities
NFTs
NFT Release Calendar
What is a Non-Fungible Token (NFT)?
How to Buy Non-Fungible Tokens (NFTs)
CryptoPunks Watchlist
Are NFTs a Scam or a Digital Bubble?
Best In Crypto
Best Crypto Apps
Best Crypto Portfolio Trackers
Best Crypto Day Trading Strategies
Best Crypto IRA
Best Cryptocurrency Scanners
Best Business Crypto Accounts
Best Crypto Screeners
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Acumen Pharmaceuticals Inc

(NASDAQ:ABOS)

$4.25

0.10[2.41%]

Last update: 9:18AM (Delayed 15-Minutes)
Get Real Time Here

$4.25

0[0.00%]

Open4.150	Close4.170
Vol / Avg.360.126K / 1.116M	Mkt Cap245.941M
Day Range4.040 - 4.225	52 Wk Range3.520 - 11.310

0

Latest News for Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

Acumen Pharmaceuticals Stock (NASDAQ: ABOS)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, September 06, 2023

Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
David Willey - Sponsored

Wednesday, August 09, 2023

Credit Suisse Reiterates Outperform on Acumen Pharmaceuticals, Maintains $13 Price Target
Benzinga Newsdesk - Aug 9, 2023, 9:02AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Aug 9, 2023, 6:30AM

Tuesday, August 08, 2023

Acumen Pharmaceuticals Q2 EPS $(0.28) Beats $(0.36) Estimate
Benzinga Newsdesk - Aug 8, 2023, 7:02AM
Earnings Scheduled For August 8, 2023
Benzinga Insights - Aug 8, 2023, 4:48AM

Monday, August 07, 2023

Acumen Pharmaceuticals's Earnings: A Preview
Benzinga Insights - Aug 7, 2023, 5:01PM

Wednesday, July 26, 2023

Director At This Health Care Company Buys $40.00M of Stock
Benzinga Insights - Jul 26, 2023, 11:02AM
$40M Bet On Acumen Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
Lisa Levin - Jul 26, 2023, 8:50AM
Neuroinflammation A Key Indicator For Alzheimer's, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
David Willey - Sponsored

Thursday, July 20, 2023

B of A Securities Reinstates Buy on Acumen Pharmaceuticals, Announces $14 Price Target
Benzinga Newsdesk - Jul 20, 2023, 6:52AM

Wednesday, July 19, 2023

Acumen Pharmaceuticals Upsizes Its Previously Announced Offering To $130M From $100M, Pricing 16,774,193 Shares Offering At $7.75/Share
Benzinga Newsdesk - Jul 19, 2023, 1:09AM

Tuesday, July 18, 2023

Acumen Pharmaceuticals shares are trading lower after the company announced a $100 million underwritten public offering.
Benzinga Newsdesk - Jul 18, 2023, 3:21PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Jul 18, 2023, 1:31PM
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Jul 18, 2023, 1:00PM
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 18, 2023, 8:12AM
Masimo, Acumen Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Lisa Levin - Jul 18, 2023, 6:46AM

Monday, July 17, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Jul 17, 2023, 5:32PM
Acumen Pharmaceuticals Commence Public Offering Of $100M Of Shares Of Its Common Stock
Benzinga Newsdesk - Jul 17, 2023, 4:55PM
Acumen Pharmaceuticals Plans To File A Preliminary Prospectus Supplement With The SEC For A Proposed Offering Of Common Stock, And As Of June 30, 2023, The Company Had Approximately $172.2M In Cash And Marketable Securities
Happy Mohamed - Jul 17, 2023, 4:50PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Jul 17, 2023, 1:31PM
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Jul 17, 2023, 1:14PM
Ford Motor Cuts Prices For F-150 Lightning Truck, Microsoft-Sony Sign Agreement for 'Call of Duty,' Alibaba Stock Slips on China's Q2 GDP Sentiment: Today's Top Stories
Vandana Singh - Jul 17, 2023, 10:13AM
US Stocks Edge Higher; NY Empire State Manufacturing Index Falls In July
Lisa Levin - Jul 17, 2023, 10:01AM
Cantor Fitzgerald Reiterates Overweight on Acumen Pharmaceuticals, Maintains $13 Price Target
Benzinga Newsdesk - Jul 17, 2023, 9:51AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Jul 17, 2023, 9:06AM
Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 17, 2023, 8:45AM
Market-Moving News for July 17th
Benzinga Newsdesk - Jul 17, 2023, 8:41AM
Acumen Pharma's Stock Doubles In One Session - Here's Why
Vandana Singh - Jul 17, 2023, 8:41AM
Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Lisa Levin - Jul 17, 2023, 7:27AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Jul 17, 2023, 6:19AM
Acumen Pharmaceuticals shares are trading higher after the company presented topline results from Phase 1 study of ACU193 for early Alzheimer's disease at the Alzheimer's Association International Conference 2023.
Benzinga Newsdesk - Jul 17, 2023, 4:53AM
Sunday, Acumen Presented Topline Results From Phase 1 Study Of ACU193 For Early Alzheimer's Disease; The Trial Met Primary And Secondary Objectives
Benzinga Newsdesk - Jul 17, 2023, 4:52AM

Tuesday, July 11, 2023

Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Jul 11, 2023, 1:26PM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights - Jul 11, 2023, 9:12AM
Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 11, 2023, 8:33AM

Tuesday, June 13, 2023

12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Jun 13, 2023, 1:31PM
Acumen Pharmaceuticals shares are trading higher after the company announced it will present topline results from a Phase 1 trial of its candidate ACI193 at the Alzheimer's Association International Conference in July.
Benzinga Newsdesk - Jun 13, 2023, 11:33AM
Acumen Pharmaceuticals To Present Topline Results From First-in-human Phase 1 Study Of ACU193 For Early Alzheimer's Disease During Featured Research Session At The Alzheimer's Association International Conference 2023 On 16 July
Benzinga Newsdesk - Jun 13, 2023, 7:10AM

Thursday, June 08, 2023

Director at Acumen Pharmaceuticals Acquires Company Stock Options Worth 25,000 Shares
Benzinga Insights - Jun 8, 2023, 11:02AM
Board Member at Acumen Pharmaceuticals Acquires Company Stock Options Worth 25,000 Shares
Benzinga Insights - Jun 8, 2023, 11:02AM
Acumen Pharmaceuticals Board Member Awarded $123K Worth of Stock Options
Benzinga Insights - Jun 8, 2023, 11:02AM

Thursday, May 18, 2023

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Benzinga Insights - May 18, 2023, 11:00AM
Cantor Fitzgerald Initiates Coverage On Acumen Pharmaceuticals with Overweight Rating, Announces Price Target of $13
Benzinga Newsdesk - May 18, 2023, 8:52AM

Wednesday, May 10, 2023

Top 5 Health Care Stocks That May Collapse In Q2
Lisa Levin - May 10, 2023, 7:53AM

Tuesday, May 09, 2023

Acumen Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 EPS results.
Benzinga Newsdesk - May 9, 2023, 1:22PM
Acumen Pharmaceuticals Q1 EPS $(0.28) Beats $(0.35) Estimate
Benzinga Newsdesk - May 9, 2023, 7:05AM
Earnings Scheduled For May 9, 2023
Benzinga Insights - May 9, 2023, 6:03AM

Monday, May 08, 2023

Earnings Outlook For Acumen Pharmaceuticals
Benzinga Insights - May 8, 2023, 4:01PM

Tuesday, March 28, 2023

Credit Suisse Maintains Outperform on Acumen Pharmaceuticals, Lowers Price Target to $13
Benzinga Newsdesk - Mar 28, 2023, 7:11AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Mar 28, 2023, 6:38AM

1
2
3
4
5
6
7
Next
17

Latest News for Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

Acumen Pharmaceuticals Stock (NASDAQ: ABOS)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, September 06, 2023

Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
David Willey - Sponsored

Wednesday, August 09, 2023

Credit Suisse Reiterates Outperform on Acumen Pharmaceuticals, Maintains $13 Price Target
Benzinga Newsdesk - Aug 9, 2023, 9:02AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Aug 9, 2023, 6:30AM

Tuesday, August 08, 2023

Acumen Pharmaceuticals Q2 EPS $(0.28) Beats $(0.36) Estimate
Benzinga Newsdesk - Aug 8, 2023, 7:02AM
Earnings Scheduled For August 8, 2023
Benzinga Insights - Aug 8, 2023, 4:48AM

Monday, August 07, 2023

Acumen Pharmaceuticals's Earnings: A Preview
Benzinga Insights - Aug 7, 2023, 5:01PM

Wednesday, July 26, 2023

Director At This Health Care Company Buys $40.00M of Stock
Benzinga Insights - Jul 26, 2023, 11:02AM
$40M Bet On Acumen Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
Lisa Levin - Jul 26, 2023, 8:50AM
Neuroinflammation A Key Indicator For Alzheimer's, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
David Willey - Sponsored

Thursday, July 20, 2023

B of A Securities Reinstates Buy on Acumen Pharmaceuticals, Announces $14 Price Target
Benzinga Newsdesk - Jul 20, 2023, 6:52AM

Wednesday, July 19, 2023

Acumen Pharmaceuticals Upsizes Its Previously Announced Offering To $130M From $100M, Pricing 16,774,193 Shares Offering At $7.75/Share
Benzinga Newsdesk - Jul 19, 2023, 1:09AM

Tuesday, July 18, 2023

Acumen Pharmaceuticals shares are trading lower after the company announced a $100 million underwritten public offering.
Benzinga Newsdesk - Jul 18, 2023, 3:21PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Jul 18, 2023, 1:31PM
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Jul 18, 2023, 1:00PM
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 18, 2023, 8:12AM
Masimo, Acumen Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Lisa Levin - Jul 18, 2023, 6:46AM

Monday, July 17, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Jul 17, 2023, 5:32PM
Acumen Pharmaceuticals Commence Public Offering Of $100M Of Shares Of Its Common Stock
Benzinga Newsdesk - Jul 17, 2023, 4:55PM
Acumen Pharmaceuticals Plans To File A Preliminary Prospectus Supplement With The SEC For A Proposed Offering Of Common Stock, And As Of June 30, 2023, The Company Had Approximately $172.2M In Cash And Marketable Securities
Happy Mohamed - Jul 17, 2023, 4:50PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Jul 17, 2023, 1:31PM
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Jul 17, 2023, 1:14PM
Ford Motor Cuts Prices For F-150 Lightning Truck, Microsoft-Sony Sign Agreement for 'Call of Duty,' Alibaba Stock Slips on China's Q2 GDP Sentiment: Today's Top Stories
Vandana Singh - Jul 17, 2023, 10:13AM
US Stocks Edge Higher; NY Empire State Manufacturing Index Falls In July
Lisa Levin - Jul 17, 2023, 10:01AM
Cantor Fitzgerald Reiterates Overweight on Acumen Pharmaceuticals, Maintains $13 Price Target
Benzinga Newsdesk - Jul 17, 2023, 9:51AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Jul 17, 2023, 9:06AM
Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 17, 2023, 8:45AM
Market-Moving News for July 17th
Benzinga Newsdesk - Jul 17, 2023, 8:41AM
Acumen Pharma's Stock Doubles In One Session - Here's Why
Vandana Singh - Jul 17, 2023, 8:41AM
Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Lisa Levin - Jul 17, 2023, 7:27AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Jul 17, 2023, 6:19AM
Acumen Pharmaceuticals shares are trading higher after the company presented topline results from Phase 1 study of ACU193 for early Alzheimer's disease at the Alzheimer's Association International Conference 2023.
Benzinga Newsdesk - Jul 17, 2023, 4:53AM
Sunday, Acumen Presented Topline Results From Phase 1 Study Of ACU193 For Early Alzheimer's Disease; The Trial Met Primary And Secondary Objectives
Benzinga Newsdesk - Jul 17, 2023, 4:52AM

Tuesday, July 11, 2023

Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Jul 11, 2023, 1:26PM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights - Jul 11, 2023, 9:12AM
Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 11, 2023, 8:33AM

Tuesday, June 13, 2023

12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Jun 13, 2023, 1:31PM
Acumen Pharmaceuticals shares are trading higher after the company announced it will present topline results from a Phase 1 trial of its candidate ACI193 at the Alzheimer's Association International Conference in July.
Benzinga Newsdesk - Jun 13, 2023, 11:33AM
Acumen Pharmaceuticals To Present Topline Results From First-in-human Phase 1 Study Of ACU193 For Early Alzheimer's Disease During Featured Research Session At The Alzheimer's Association International Conference 2023 On 16 July
Benzinga Newsdesk - Jun 13, 2023, 7:10AM

Thursday, June 08, 2023

Director at Acumen Pharmaceuticals Acquires Company Stock Options Worth 25,000 Shares
Benzinga Insights - Jun 8, 2023, 11:02AM
Board Member at Acumen Pharmaceuticals Acquires Company Stock Options Worth 25,000 Shares
Benzinga Insights - Jun 8, 2023, 11:02AM
Acumen Pharmaceuticals Board Member Awarded $123K Worth of Stock Options
Benzinga Insights - Jun 8, 2023, 11:02AM

Thursday, May 18, 2023

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Benzinga Insights - May 18, 2023, 11:00AM
Cantor Fitzgerald Initiates Coverage On Acumen Pharmaceuticals with Overweight Rating, Announces Price Target of $13
Benzinga Newsdesk - May 18, 2023, 8:52AM

Wednesday, May 10, 2023

Top 5 Health Care Stocks That May Collapse In Q2
Lisa Levin - May 10, 2023, 7:53AM

Tuesday, May 09, 2023

Acumen Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 EPS results.
Benzinga Newsdesk - May 9, 2023, 1:22PM
Acumen Pharmaceuticals Q1 EPS $(0.28) Beats $(0.35) Estimate
Benzinga Newsdesk - May 9, 2023, 7:05AM
Earnings Scheduled For May 9, 2023
Benzinga Insights - May 9, 2023, 6:03AM

Monday, May 08, 2023

Earnings Outlook For Acumen Pharmaceuticals
Benzinga Insights - May 8, 2023, 4:01PM

Tuesday, March 28, 2023

Credit Suisse Maintains Outperform on Acumen Pharmaceuticals, Lowers Price Target to $13
Benzinga Newsdesk - Mar 28, 2023, 7:11AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Mar 28, 2023, 6:38AM

1
2
3
4
5
6
7
Next
17

Latest News for Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

Acumen Pharmaceuticals Stock (NASDAQ: ABOS)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, September 06, 2023

Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
David Willey - Sponsored

Wednesday, August 09, 2023

Credit Suisse Reiterates Outperform on Acumen Pharmaceuticals, Maintains $13 Price Target
Benzinga Newsdesk - Aug 9, 2023, 9:02AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Aug 9, 2023, 6:30AM

Tuesday, August 08, 2023

Acumen Pharmaceuticals Q2 EPS $(0.28) Beats $(0.36) Estimate
Benzinga Newsdesk - Aug 8, 2023, 7:02AM
Earnings Scheduled For August 8, 2023
Benzinga Insights - Aug 8, 2023, 4:48AM

Monday, August 07, 2023

Acumen Pharmaceuticals's Earnings: A Preview
Benzinga Insights - Aug 7, 2023, 5:01PM

Wednesday, July 26, 2023

Director At This Health Care Company Buys $40.00M of Stock
Benzinga Insights - Jul 26, 2023, 11:02AM
$40M Bet On Acumen Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
Lisa Levin - Jul 26, 2023, 8:50AM
Neuroinflammation A Key Indicator For Alzheimer's, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
David Willey - Sponsored

Thursday, July 20, 2023

B of A Securities Reinstates Buy on Acumen Pharmaceuticals, Announces $14 Price Target
Benzinga Newsdesk - Jul 20, 2023, 6:52AM

Wednesday, July 19, 2023

Acumen Pharmaceuticals Upsizes Its Previously Announced Offering To $130M From $100M, Pricing 16,774,193 Shares Offering At $7.75/Share
Benzinga Newsdesk - Jul 19, 2023, 1:09AM

Tuesday, July 18, 2023

Acumen Pharmaceuticals shares are trading lower after the company announced a $100 million underwritten public offering.
Benzinga Newsdesk - Jul 18, 2023, 3:21PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Jul 18, 2023, 1:31PM
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Jul 18, 2023, 1:00PM
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 18, 2023, 8:12AM
Masimo, Acumen Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Lisa Levin - Jul 18, 2023, 6:46AM

Monday, July 17, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Jul 17, 2023, 5:32PM
Acumen Pharmaceuticals Commence Public Offering Of $100M Of Shares Of Its Common Stock
Benzinga Newsdesk - Jul 17, 2023, 4:55PM
Acumen Pharmaceuticals Plans To File A Preliminary Prospectus Supplement With The SEC For A Proposed Offering Of Common Stock, And As Of June 30, 2023, The Company Had Approximately $172.2M In Cash And Marketable Securities
Happy Mohamed - Jul 17, 2023, 4:50PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Jul 17, 2023, 1:31PM
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Jul 17, 2023, 1:14PM
Ford Motor Cuts Prices For F-150 Lightning Truck, Microsoft-Sony Sign Agreement for 'Call of Duty,' Alibaba Stock Slips on China's Q2 GDP Sentiment: Today's Top Stories
Vandana Singh - Jul 17, 2023, 10:13AM
US Stocks Edge Higher; NY Empire State Manufacturing Index Falls In July
Lisa Levin - Jul 17, 2023, 10:01AM
Cantor Fitzgerald Reiterates Overweight on Acumen Pharmaceuticals, Maintains $13 Price Target
Benzinga Newsdesk - Jul 17, 2023, 9:51AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Jul 17, 2023, 9:06AM
Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 17, 2023, 8:45AM
Market-Moving News for July 17th
Benzinga Newsdesk - Jul 17, 2023, 8:41AM
Acumen Pharma's Stock Doubles In One Session - Here's Why
Vandana Singh - Jul 17, 2023, 8:41AM
Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Lisa Levin - Jul 17, 2023, 7:27AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Jul 17, 2023, 6:19AM
Acumen Pharmaceuticals shares are trading higher after the company presented topline results from Phase 1 study of ACU193 for early Alzheimer's disease at the Alzheimer's Association International Conference 2023.
Benzinga Newsdesk - Jul 17, 2023, 4:53AM
Sunday, Acumen Presented Topline Results From Phase 1 Study Of ACU193 For Early Alzheimer's Disease; The Trial Met Primary And Secondary Objectives
Benzinga Newsdesk - Jul 17, 2023, 4:52AM

Tuesday, July 11, 2023

Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Jul 11, 2023, 1:26PM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights - Jul 11, 2023, 9:12AM
Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 11, 2023, 8:33AM

Tuesday, June 13, 2023

12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Jun 13, 2023, 1:31PM
Acumen Pharmaceuticals shares are trading higher after the company announced it will present topline results from a Phase 1 trial of its candidate ACI193 at the Alzheimer's Association International Conference in July.
Benzinga Newsdesk - Jun 13, 2023, 11:33AM
Acumen Pharmaceuticals To Present Topline Results From First-in-human Phase 1 Study Of ACU193 For Early Alzheimer's Disease During Featured Research Session At The Alzheimer's Association International Conference 2023 On 16 July
Benzinga Newsdesk - Jun 13, 2023, 7:10AM

Thursday, June 08, 2023

Director at Acumen Pharmaceuticals Acquires Company Stock Options Worth 25,000 Shares
Benzinga Insights - Jun 8, 2023, 11:02AM
Board Member at Acumen Pharmaceuticals Acquires Company Stock Options Worth 25,000 Shares
Benzinga Insights - Jun 8, 2023, 11:02AM
Acumen Pharmaceuticals Board Member Awarded $123K Worth of Stock Options
Benzinga Insights - Jun 8, 2023, 11:02AM

Thursday, May 18, 2023

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Benzinga Insights - May 18, 2023, 11:00AM
Cantor Fitzgerald Initiates Coverage On Acumen Pharmaceuticals with Overweight Rating, Announces Price Target of $13
Benzinga Newsdesk - May 18, 2023, 8:52AM

Wednesday, May 10, 2023

Top 5 Health Care Stocks That May Collapse In Q2
Lisa Levin - May 10, 2023, 7:53AM

Tuesday, May 09, 2023

Acumen Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 EPS results.
Benzinga Newsdesk - May 9, 2023, 1:22PM
Acumen Pharmaceuticals Q1 EPS $(0.28) Beats $(0.35) Estimate
Benzinga Newsdesk - May 9, 2023, 7:05AM
Earnings Scheduled For May 9, 2023
Benzinga Insights - May 9, 2023, 6:03AM

Monday, May 08, 2023

Earnings Outlook For Acumen Pharmaceuticals
Benzinga Insights - May 8, 2023, 4:01PM

Tuesday, March 28, 2023

Credit Suisse Maintains Outperform on Acumen Pharmaceuticals, Lowers Price Target to $13
Benzinga Newsdesk - Mar 28, 2023, 7:11AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Mar 28, 2023, 6:38AM

1
2
3
4
5
6
7
Next
17

Latest News for Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

Acumen Pharmaceuticals Stock (NASDAQ: ABOS)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, September 06, 2023

Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
David Willey - Sponsored

Wednesday, August 09, 2023

Credit Suisse Reiterates Outperform on Acumen Pharmaceuticals, Maintains $13 Price Target
Benzinga Newsdesk - Aug 9, 2023, 9:02AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Aug 9, 2023, 6:30AM

Tuesday, August 08, 2023

Acumen Pharmaceuticals Q2 EPS $(0.28) Beats $(0.36) Estimate
Benzinga Newsdesk - Aug 8, 2023, 7:02AM
Earnings Scheduled For August 8, 2023
Benzinga Insights - Aug 8, 2023, 4:48AM

Monday, August 07, 2023

Acumen Pharmaceuticals's Earnings: A Preview
Benzinga Insights - Aug 7, 2023, 5:01PM

Wednesday, July 26, 2023

Director At This Health Care Company Buys $40.00M of Stock
Benzinga Insights - Jul 26, 2023, 11:02AM
$40M Bet On Acumen Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
Lisa Levin - Jul 26, 2023, 8:50AM
Neuroinflammation A Key Indicator For Alzheimer's, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
David Willey - Sponsored

Thursday, July 20, 2023

B of A Securities Reinstates Buy on Acumen Pharmaceuticals, Announces $14 Price Target
Benzinga Newsdesk - Jul 20, 2023, 6:52AM

Wednesday, July 19, 2023

Acumen Pharmaceuticals Upsizes Its Previously Announced Offering To $130M From $100M, Pricing 16,774,193 Shares Offering At $7.75/Share
Benzinga Newsdesk - Jul 19, 2023, 1:09AM

Tuesday, July 18, 2023

Acumen Pharmaceuticals shares are trading lower after the company announced a $100 million underwritten public offering.
Benzinga Newsdesk - Jul 18, 2023, 3:21PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Jul 18, 2023, 1:31PM
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Jul 18, 2023, 1:00PM
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 18, 2023, 8:12AM
Masimo, Acumen Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Lisa Levin - Jul 18, 2023, 6:46AM

Monday, July 17, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Jul 17, 2023, 5:32PM
Acumen Pharmaceuticals Commence Public Offering Of $100M Of Shares Of Its Common Stock
Benzinga Newsdesk - Jul 17, 2023, 4:55PM
Acumen Pharmaceuticals Plans To File A Preliminary Prospectus Supplement With The SEC For A Proposed Offering Of Common Stock, And As Of June 30, 2023, The Company Had Approximately $172.2M In Cash And Marketable Securities
Happy Mohamed - Jul 17, 2023, 4:50PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Jul 17, 2023, 1:31PM
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Jul 17, 2023, 1:14PM
Ford Motor Cuts Prices For F-150 Lightning Truck, Microsoft-Sony Sign Agreement for 'Call of Duty,' Alibaba Stock Slips on China's Q2 GDP Sentiment: Today's Top Stories
Vandana Singh - Jul 17, 2023, 10:13AM
US Stocks Edge Higher; NY Empire State Manufacturing Index Falls In July
Lisa Levin - Jul 17, 2023, 10:01AM
Cantor Fitzgerald Reiterates Overweight on Acumen Pharmaceuticals, Maintains $13 Price Target
Benzinga Newsdesk - Jul 17, 2023, 9:51AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Jul 17, 2023, 9:06AM
Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 17, 2023, 8:45AM
Market-Moving News for July 17th
Benzinga Newsdesk - Jul 17, 2023, 8:41AM
Acumen Pharma's Stock Doubles In One Session - Here's Why
Vandana Singh - Jul 17, 2023, 8:41AM
Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Lisa Levin - Jul 17, 2023, 7:27AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Jul 17, 2023, 6:19AM
Acumen Pharmaceuticals shares are trading higher after the company presented topline results from Phase 1 study of ACU193 for early Alzheimer's disease at the Alzheimer's Association International Conference 2023.
Benzinga Newsdesk - Jul 17, 2023, 4:53AM
Sunday, Acumen Presented Topline Results From Phase 1 Study Of ACU193 For Early Alzheimer's Disease; The Trial Met Primary And Secondary Objectives
Benzinga Newsdesk - Jul 17, 2023, 4:52AM

Tuesday, July 11, 2023

Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Jul 11, 2023, 1:26PM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights - Jul 11, 2023, 9:12AM
Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 11, 2023, 8:33AM

Tuesday, June 13, 2023

12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Jun 13, 2023, 1:31PM
Acumen Pharmaceuticals shares are trading higher after the company announced it will present topline results from a Phase 1 trial of its candidate ACI193 at the Alzheimer's Association International Conference in July.
Benzinga Newsdesk - Jun 13, 2023, 11:33AM
Acumen Pharmaceuticals To Present Topline Results From First-in-human Phase 1 Study Of ACU193 For Early Alzheimer's Disease During Featured Research Session At The Alzheimer's Association International Conference 2023 On 16 July
Benzinga Newsdesk - Jun 13, 2023, 7:10AM

Thursday, June 08, 2023

Director at Acumen Pharmaceuticals Acquires Company Stock Options Worth 25,000 Shares
Benzinga Insights - Jun 8, 2023, 11:02AM
Board Member at Acumen Pharmaceuticals Acquires Company Stock Options Worth 25,000 Shares
Benzinga Insights - Jun 8, 2023, 11:02AM
Acumen Pharmaceuticals Board Member Awarded $123K Worth of Stock Options
Benzinga Insights - Jun 8, 2023, 11:02AM

Thursday, May 18, 2023

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Benzinga Insights - May 18, 2023, 11:00AM
Cantor Fitzgerald Initiates Coverage On Acumen Pharmaceuticals with Overweight Rating, Announces Price Target of $13
Benzinga Newsdesk - May 18, 2023, 8:52AM

Wednesday, May 10, 2023

Top 5 Health Care Stocks That May Collapse In Q2
Lisa Levin - May 10, 2023, 7:53AM

Tuesday, May 09, 2023

Acumen Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 EPS results.
Benzinga Newsdesk - May 9, 2023, 1:22PM
Acumen Pharmaceuticals Q1 EPS $(0.28) Beats $(0.35) Estimate
Benzinga Newsdesk - May 9, 2023, 7:05AM
Earnings Scheduled For May 9, 2023
Benzinga Insights - May 9, 2023, 6:03AM

Monday, May 08, 2023

Earnings Outlook For Acumen Pharmaceuticals
Benzinga Insights - May 8, 2023, 4:01PM

Tuesday, March 28, 2023

Credit Suisse Maintains Outperform on Acumen Pharmaceuticals, Lowers Price Target to $13
Benzinga Newsdesk - Mar 28, 2023, 7:11AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Mar 28, 2023, 6:38AM

1
2
3
4
5
6
7
Next
17

Latest News for Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

Acumen Pharmaceuticals Stock (NASDAQ: ABOS)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, September 06, 2023

Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
David Willey - Sponsored

Wednesday, August 09, 2023

Credit Suisse Reiterates Outperform on Acumen Pharmaceuticals, Maintains $13 Price Target
Benzinga Newsdesk - Aug 9, 2023, 9:02AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Aug 9, 2023, 6:30AM

Tuesday, August 08, 2023

Acumen Pharmaceuticals Q2 EPS $(0.28) Beats $(0.36) Estimate
Benzinga Newsdesk - Aug 8, 2023, 7:02AM
Earnings Scheduled For August 8, 2023
Benzinga Insights - Aug 8, 2023, 4:48AM

Monday, August 07, 2023

Acumen Pharmaceuticals's Earnings: A Preview
Benzinga Insights - Aug 7, 2023, 5:01PM

Wednesday, July 26, 2023

Director At This Health Care Company Buys $40.00M of Stock
Benzinga Insights - Jul 26, 2023, 11:02AM
$40M Bet On Acumen Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
Lisa Levin - Jul 26, 2023, 8:50AM
Neuroinflammation A Key Indicator For Alzheimer's, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
David Willey - Sponsored

Thursday, July 20, 2023

B of A Securities Reinstates Buy on Acumen Pharmaceuticals, Announces $14 Price Target
Benzinga Newsdesk - Jul 20, 2023, 6:52AM

Wednesday, July 19, 2023

Acumen Pharmaceuticals Upsizes Its Previously Announced Offering To $130M From $100M, Pricing 16,774,193 Shares Offering At $7.75/Share
Benzinga Newsdesk - Jul 19, 2023, 1:09AM

Tuesday, July 18, 2023

Acumen Pharmaceuticals shares are trading lower after the company announced a $100 million underwritten public offering.
Benzinga Newsdesk - Jul 18, 2023, 3:21PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Jul 18, 2023, 1:31PM
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Jul 18, 2023, 1:00PM
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 18, 2023, 8:12AM
Masimo, Acumen Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Lisa Levin - Jul 18, 2023, 6:46AM

Monday, July 17, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Jul 17, 2023, 5:32PM
Acumen Pharmaceuticals Commence Public Offering Of $100M Of Shares Of Its Common Stock
Benzinga Newsdesk - Jul 17, 2023, 4:55PM
Acumen Pharmaceuticals Plans To File A Preliminary Prospectus Supplement With The SEC For A Proposed Offering Of Common Stock, And As Of June 30, 2023, The Company Had Approximately $172.2M In Cash And Marketable Securities
Happy Mohamed - Jul 17, 2023, 4:50PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Jul 17, 2023, 1:31PM
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Jul 17, 2023, 1:14PM
Ford Motor Cuts Prices For F-150 Lightning Truck, Microsoft-Sony Sign Agreement for 'Call of Duty,' Alibaba Stock Slips on China's Q2 GDP Sentiment: Today's Top Stories
Vandana Singh - Jul 17, 2023, 10:13AM
US Stocks Edge Higher; NY Empire State Manufacturing Index Falls In July
Lisa Levin - Jul 17, 2023, 10:01AM
Cantor Fitzgerald Reiterates Overweight on Acumen Pharmaceuticals, Maintains $13 Price Target
Benzinga Newsdesk - Jul 17, 2023, 9:51AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Jul 17, 2023, 9:06AM
Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 17, 2023, 8:45AM
Market-Moving News for July 17th
Benzinga Newsdesk - Jul 17, 2023, 8:41AM
Acumen Pharma's Stock Doubles In One Session - Here's Why
Vandana Singh - Jul 17, 2023, 8:41AM
Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Lisa Levin - Jul 17, 2023, 7:27AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Jul 17, 2023, 6:19AM
Acumen Pharmaceuticals shares are trading higher after the company presented topline results from Phase 1 study of ACU193 for early Alzheimer's disease at the Alzheimer's Association International Conference 2023.
Benzinga Newsdesk - Jul 17, 2023, 4:53AM
Sunday, Acumen Presented Topline Results From Phase 1 Study Of ACU193 For Early Alzheimer's Disease; The Trial Met Primary And Secondary Objectives
Benzinga Newsdesk - Jul 17, 2023, 4:52AM

Tuesday, July 11, 2023

Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Jul 11, 2023, 1:26PM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights - Jul 11, 2023, 9:12AM
Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 11, 2023, 8:33AM

Tuesday, June 13, 2023

12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Jun 13, 2023, 1:31PM
Acumen Pharmaceuticals shares are trading higher after the company announced it will present topline results from a Phase 1 trial of its candidate ACI193 at the Alzheimer's Association International Conference in July.
Benzinga Newsdesk - Jun 13, 2023, 11:33AM
Acumen Pharmaceuticals To Present Topline Results From First-in-human Phase 1 Study Of ACU193 For Early Alzheimer's Disease During Featured Research Session At The Alzheimer's Association International Conference 2023 On 16 July
Benzinga Newsdesk - Jun 13, 2023, 7:10AM

Thursday, June 08, 2023

Director at Acumen Pharmaceuticals Acquires Company Stock Options Worth 25,000 Shares
Benzinga Insights - Jun 8, 2023, 11:02AM
Board Member at Acumen Pharmaceuticals Acquires Company Stock Options Worth 25,000 Shares
Benzinga Insights - Jun 8, 2023, 11:02AM
Acumen Pharmaceuticals Board Member Awarded $123K Worth of Stock Options
Benzinga Insights - Jun 8, 2023, 11:02AM

Thursday, May 18, 2023

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Benzinga Insights - May 18, 2023, 11:00AM
Cantor Fitzgerald Initiates Coverage On Acumen Pharmaceuticals with Overweight Rating, Announces Price Target of $13
Benzinga Newsdesk - May 18, 2023, 8:52AM

Wednesday, May 10, 2023

Top 5 Health Care Stocks That May Collapse In Q2
Lisa Levin - May 10, 2023, 7:53AM

Tuesday, May 09, 2023

Acumen Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 EPS results.
Benzinga Newsdesk - May 9, 2023, 1:22PM
Acumen Pharmaceuticals Q1 EPS $(0.28) Beats $(0.35) Estimate
Benzinga Newsdesk - May 9, 2023, 7:05AM
Earnings Scheduled For May 9, 2023
Benzinga Insights - May 9, 2023, 6:03AM

Monday, May 08, 2023

Earnings Outlook For Acumen Pharmaceuticals
Benzinga Insights - May 8, 2023, 4:01PM

Tuesday, March 28, 2023

Credit Suisse Maintains Outperform on Acumen Pharmaceuticals, Lowers Price Target to $13
Benzinga Newsdesk - Mar 28, 2023, 7:11AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Mar 28, 2023, 6:38AM

1
2
3
4
5
6
7
Next
17

Latest News for Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

Acumen Pharmaceuticals Stock (NASDAQ: ABOS)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, September 06, 2023

Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
David Willey - Sponsored

Wednesday, August 09, 2023

Credit Suisse Reiterates Outperform on Acumen Pharmaceuticals, Maintains $13 Price Target
Benzinga Newsdesk - Aug 9, 2023, 9:02AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Aug 9, 2023, 6:30AM

Tuesday, August 08, 2023

Acumen Pharmaceuticals Q2 EPS $(0.28) Beats $(0.36) Estimate
Benzinga Newsdesk - Aug 8, 2023, 7:02AM
Earnings Scheduled For August 8, 2023
Benzinga Insights - Aug 8, 2023, 4:48AM

Monday, August 07, 2023

Acumen Pharmaceuticals's Earnings: A Preview
Benzinga Insights - Aug 7, 2023, 5:01PM

Wednesday, July 26, 2023

Director At This Health Care Company Buys $40.00M of Stock
Benzinga Insights - Jul 26, 2023, 11:02AM
$40M Bet On Acumen Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
Lisa Levin - Jul 26, 2023, 8:50AM
Neuroinflammation A Key Indicator For Alzheimer's, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
David Willey - Sponsored

Thursday, July 20, 2023

B of A Securities Reinstates Buy on Acumen Pharmaceuticals, Announces $14 Price Target
Benzinga Newsdesk - Jul 20, 2023, 6:52AM

Wednesday, July 19, 2023

Acumen Pharmaceuticals Upsizes Its Previously Announced Offering To $130M From $100M, Pricing 16,774,193 Shares Offering At $7.75/Share
Benzinga Newsdesk - Jul 19, 2023, 1:09AM

Tuesday, July 18, 2023

Acumen Pharmaceuticals shares are trading lower after the company announced a $100 million underwritten public offering.
Benzinga Newsdesk - Jul 18, 2023, 3:21PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Jul 18, 2023, 1:31PM
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Jul 18, 2023, 1:00PM
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 18, 2023, 8:12AM
Masimo, Acumen Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Lisa Levin - Jul 18, 2023, 6:46AM

Monday, July 17, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Jul 17, 2023, 5:32PM
Acumen Pharmaceuticals Commence Public Offering Of $100M Of Shares Of Its Common Stock
Benzinga Newsdesk - Jul 17, 2023, 4:55PM
Acumen Pharmaceuticals Plans To File A Preliminary Prospectus Supplement With The SEC For A Proposed Offering Of Common Stock, And As Of June 30, 2023, The Company Had Approximately $172.2M In Cash And Marketable Securities
Happy Mohamed - Jul 17, 2023, 4:50PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Jul 17, 2023, 1:31PM
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Jul 17, 2023, 1:14PM
Ford Motor Cuts Prices For F-150 Lightning Truck, Microsoft-Sony Sign Agreement for 'Call of Duty,' Alibaba Stock Slips on China's Q2 GDP Sentiment: Today's Top Stories
Vandana Singh - Jul 17, 2023, 10:13AM
US Stocks Edge Higher; NY Empire State Manufacturing Index Falls In July
Lisa Levin - Jul 17, 2023, 10:01AM
Cantor Fitzgerald Reiterates Overweight on Acumen Pharmaceuticals, Maintains $13 Price Target
Benzinga Newsdesk - Jul 17, 2023, 9:51AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Jul 17, 2023, 9:06AM
Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 17, 2023, 8:45AM
Market-Moving News for July 17th
Benzinga Newsdesk - Jul 17, 2023, 8:41AM
Acumen Pharma's Stock Doubles In One Session - Here's Why
Vandana Singh - Jul 17, 2023, 8:41AM
Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Lisa Levin - Jul 17, 2023, 7:27AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Jul 17, 2023, 6:19AM
Acumen Pharmaceuticals shares are trading higher after the company presented topline results from Phase 1 study of ACU193 for early Alzheimer's disease at the Alzheimer's Association International Conference 2023.
Benzinga Newsdesk - Jul 17, 2023, 4:53AM
Sunday, Acumen Presented Topline Results From Phase 1 Study Of ACU193 For Early Alzheimer's Disease; The Trial Met Primary And Secondary Objectives
Benzinga Newsdesk - Jul 17, 2023, 4:52AM

Tuesday, July 11, 2023

Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Jul 11, 2023, 1:26PM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights - Jul 11, 2023, 9:12AM
Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 11, 2023, 8:33AM

Tuesday, June 13, 2023

12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Jun 13, 2023, 1:31PM
Acumen Pharmaceuticals shares are trading higher after the company announced it will present topline results from a Phase 1 trial of its candidate ACI193 at the Alzheimer's Association International Conference in July.
Benzinga Newsdesk - Jun 13, 2023, 11:33AM
Acumen Pharmaceuticals To Present Topline Results From First-in-human Phase 1 Study Of ACU193 For Early Alzheimer's Disease During Featured Research Session At The Alzheimer's Association International Conference 2023 On 16 July
Benzinga Newsdesk - Jun 13, 2023, 7:10AM

Thursday, June 08, 2023

Director at Acumen Pharmaceuticals Acquires Company Stock Options Worth 25,000 Shares
Benzinga Insights - Jun 8, 2023, 11:02AM
Board Member at Acumen Pharmaceuticals Acquires Company Stock Options Worth 25,000 Shares
Benzinga Insights - Jun 8, 2023, 11:02AM
Acumen Pharmaceuticals Board Member Awarded $123K Worth of Stock Options
Benzinga Insights - Jun 8, 2023, 11:02AM

Thursday, May 18, 2023

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Benzinga Insights - May 18, 2023, 11:00AM
Cantor Fitzgerald Initiates Coverage On Acumen Pharmaceuticals with Overweight Rating, Announces Price Target of $13
Benzinga Newsdesk - May 18, 2023, 8:52AM

Wednesday, May 10, 2023

Top 5 Health Care Stocks That May Collapse In Q2
Lisa Levin - May 10, 2023, 7:53AM

Tuesday, May 09, 2023

Acumen Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 EPS results.
Benzinga Newsdesk - May 9, 2023, 1:22PM
Acumen Pharmaceuticals Q1 EPS $(0.28) Beats $(0.35) Estimate
Benzinga Newsdesk - May 9, 2023, 7:05AM
Earnings Scheduled For May 9, 2023
Benzinga Insights - May 9, 2023, 6:03AM

Monday, May 08, 2023

Earnings Outlook For Acumen Pharmaceuticals
Benzinga Insights - May 8, 2023, 4:01PM

Tuesday, March 28, 2023

Credit Suisse Maintains Outperform on Acumen Pharmaceuticals, Lowers Price Target to $13
Benzinga Newsdesk - Mar 28, 2023, 7:11AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Mar 28, 2023, 6:38AM

1
2
3
4
5
6
7
Next
17

Latest News for Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

Acumen Pharmaceuticals Stock (NASDAQ: ABOS)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, September 06, 2023

Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
David Willey - Sponsored

Wednesday, August 09, 2023

Credit Suisse Reiterates Outperform on Acumen Pharmaceuticals, Maintains $13 Price Target
Benzinga Newsdesk - Aug 9, 2023, 9:02AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Aug 9, 2023, 6:30AM

Tuesday, August 08, 2023

Acumen Pharmaceuticals Q2 EPS $(0.28) Beats $(0.36) Estimate
Benzinga Newsdesk - Aug 8, 2023, 7:02AM
Earnings Scheduled For August 8, 2023
Benzinga Insights - Aug 8, 2023, 4:48AM

Monday, August 07, 2023

Acumen Pharmaceuticals's Earnings: A Preview
Benzinga Insights - Aug 7, 2023, 5:01PM

Wednesday, July 26, 2023

Director At This Health Care Company Buys $40.00M of Stock
Benzinga Insights - Jul 26, 2023, 11:02AM
$40M Bet On Acumen Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
Lisa Levin - Jul 26, 2023, 8:50AM
Neuroinflammation A Key Indicator For Alzheimer's, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
David Willey - Sponsored

Thursday, July 20, 2023

B of A Securities Reinstates Buy on Acumen Pharmaceuticals, Announces $14 Price Target
Benzinga Newsdesk - Jul 20, 2023, 6:52AM

Wednesday, July 19, 2023

Acumen Pharmaceuticals Upsizes Its Previously Announced Offering To $130M From $100M, Pricing 16,774,193 Shares Offering At $7.75/Share
Benzinga Newsdesk - Jul 19, 2023, 1:09AM

Tuesday, July 18, 2023

Acumen Pharmaceuticals shares are trading lower after the company announced a $100 million underwritten public offering.
Benzinga Newsdesk - Jul 18, 2023, 3:21PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Jul 18, 2023, 1:31PM
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Jul 18, 2023, 1:00PM
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 18, 2023, 8:12AM
Masimo, Acumen Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Lisa Levin - Jul 18, 2023, 6:46AM

Monday, July 17, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Jul 17, 2023, 5:32PM
Acumen Pharmaceuticals Commence Public Offering Of $100M Of Shares Of Its Common Stock
Benzinga Newsdesk - Jul 17, 2023, 4:55PM
Acumen Pharmaceuticals Plans To File A Preliminary Prospectus Supplement With The SEC For A Proposed Offering Of Common Stock, And As Of June 30, 2023, The Company Had Approximately $172.2M In Cash And Marketable Securities
Happy Mohamed - Jul 17, 2023, 4:50PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Jul 17, 2023, 1:31PM
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Jul 17, 2023, 1:14PM
Ford Motor Cuts Prices For F-150 Lightning Truck, Microsoft-Sony Sign Agreement for 'Call of Duty,' Alibaba Stock Slips on China's Q2 GDP Sentiment: Today's Top Stories
Vandana Singh - Jul 17, 2023, 10:13AM
US Stocks Edge Higher; NY Empire State Manufacturing Index Falls In July
Lisa Levin - Jul 17, 2023, 10:01AM
Cantor Fitzgerald Reiterates Overweight on Acumen Pharmaceuticals, Maintains $13 Price Target
Benzinga Newsdesk - Jul 17, 2023, 9:51AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Jul 17, 2023, 9:06AM
Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 17, 2023, 8:45AM
Market-Moving News for July 17th
Benzinga Newsdesk - Jul 17, 2023, 8:41AM
Acumen Pharma's Stock Doubles In One Session - Here's Why
Vandana Singh - Jul 17, 2023, 8:41AM
Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Lisa Levin - Jul 17, 2023, 7:27AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Jul 17, 2023, 6:19AM
Acumen Pharmaceuticals shares are trading higher after the company presented topline results from Phase 1 study of ACU193 for early Alzheimer's disease at the Alzheimer's Association International Conference 2023.
Benzinga Newsdesk - Jul 17, 2023, 4:53AM
Sunday, Acumen Presented Topline Results From Phase 1 Study Of ACU193 For Early Alzheimer's Disease; The Trial Met Primary And Secondary Objectives
Benzinga Newsdesk - Jul 17, 2023, 4:52AM

Tuesday, July 11, 2023

Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Jul 11, 2023, 1:26PM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights - Jul 11, 2023, 9:12AM
Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 11, 2023, 8:33AM

Tuesday, June 13, 2023

12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Jun 13, 2023, 1:31PM
Acumen Pharmaceuticals shares are trading higher after the company announced it will present topline results from a Phase 1 trial of its candidate ACI193 at the Alzheimer's Association International Conference in July.
Benzinga Newsdesk - Jun 13, 2023, 11:33AM
Acumen Pharmaceuticals To Present Topline Results From First-in-human Phase 1 Study Of ACU193 For Early Alzheimer's Disease During Featured Research Session At The Alzheimer's Association International Conference 2023 On 16 July
Benzinga Newsdesk - Jun 13, 2023, 7:10AM

Thursday, June 08, 2023

Director at Acumen Pharmaceuticals Acquires Company Stock Options Worth 25,000 Shares
Benzinga Insights - Jun 8, 2023, 11:02AM
Board Member at Acumen Pharmaceuticals Acquires Company Stock Options Worth 25,000 Shares
Benzinga Insights - Jun 8, 2023, 11:02AM
Acumen Pharmaceuticals Board Member Awarded $123K Worth of Stock Options
Benzinga Insights - Jun 8, 2023, 11:02AM

Thursday, May 18, 2023

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Benzinga Insights - May 18, 2023, 11:00AM
Cantor Fitzgerald Initiates Coverage On Acumen Pharmaceuticals with Overweight Rating, Announces Price Target of $13
Benzinga Newsdesk - May 18, 2023, 8:52AM

Wednesday, May 10, 2023

Top 5 Health Care Stocks That May Collapse In Q2
Lisa Levin - May 10, 2023, 7:53AM

Tuesday, May 09, 2023

Acumen Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 EPS results.
Benzinga Newsdesk - May 9, 2023, 1:22PM
Acumen Pharmaceuticals Q1 EPS $(0.28) Beats $(0.35) Estimate
Benzinga Newsdesk - May 9, 2023, 7:05AM
Earnings Scheduled For May 9, 2023
Benzinga Insights - May 9, 2023, 6:03AM

Monday, May 08, 2023

Earnings Outlook For Acumen Pharmaceuticals
Benzinga Insights - May 8, 2023, 4:01PM

Tuesday, March 28, 2023

Credit Suisse Maintains Outperform on Acumen Pharmaceuticals, Lowers Price Target to $13
Benzinga Newsdesk - Mar 28, 2023, 7:11AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Mar 28, 2023, 6:38AM

1
2
3
4
5
6
7
Next
17

Latest News for Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

Acumen Pharmaceuticals Stock (NASDAQ: ABOS)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, September 06, 2023

Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
David Willey - Sponsored

Wednesday, August 09, 2023

Credit Suisse Reiterates Outperform on Acumen Pharmaceuticals, Maintains $13 Price Target
Benzinga Newsdesk - Aug 9, 2023, 9:02AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Aug 9, 2023, 6:30AM

Tuesday, August 08, 2023

Acumen Pharmaceuticals Q2 EPS $(0.28) Beats $(0.36) Estimate
Benzinga Newsdesk - Aug 8, 2023, 7:02AM
Earnings Scheduled For August 8, 2023
Benzinga Insights - Aug 8, 2023, 4:48AM

Monday, August 07, 2023

Acumen Pharmaceuticals's Earnings: A Preview
Benzinga Insights - Aug 7, 2023, 5:01PM

Wednesday, July 26, 2023

Director At This Health Care Company Buys $40.00M of Stock
Benzinga Insights - Jul 26, 2023, 11:02AM
$40M Bet On Acumen Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
Lisa Levin - Jul 26, 2023, 8:50AM
Neuroinflammation A Key Indicator For Alzheimer's, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
David Willey - Sponsored

Thursday, July 20, 2023

B of A Securities Reinstates Buy on Acumen Pharmaceuticals, Announces $14 Price Target
Benzinga Newsdesk - Jul 20, 2023, 6:52AM

Wednesday, July 19, 2023

Acumen Pharmaceuticals Upsizes Its Previously Announced Offering To $130M From $100M, Pricing 16,774,193 Shares Offering At $7.75/Share
Benzinga Newsdesk - Jul 19, 2023, 1:09AM

Tuesday, July 18, 2023

Acumen Pharmaceuticals shares are trading lower after the company announced a $100 million underwritten public offering.
Benzinga Newsdesk - Jul 18, 2023, 3:21PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Jul 18, 2023, 1:31PM
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Jul 18, 2023, 1:00PM
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 18, 2023, 8:12AM
Masimo, Acumen Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Lisa Levin - Jul 18, 2023, 6:46AM

Monday, July 17, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Jul 17, 2023, 5:32PM
Acumen Pharmaceuticals Commence Public Offering Of $100M Of Shares Of Its Common Stock
Benzinga Newsdesk - Jul 17, 2023, 4:55PM
Acumen Pharmaceuticals Plans To File A Preliminary Prospectus Supplement With The SEC For A Proposed Offering Of Common Stock, And As Of June 30, 2023, The Company Had Approximately $172.2M In Cash And Marketable Securities
Happy Mohamed - Jul 17, 2023, 4:50PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Jul 17, 2023, 1:31PM
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Jul 17, 2023, 1:14PM
Ford Motor Cuts Prices For F-150 Lightning Truck, Microsoft-Sony Sign Agreement for 'Call of Duty,' Alibaba Stock Slips on China's Q2 GDP Sentiment: Today's Top Stories
Vandana Singh - Jul 17, 2023, 10:13AM
US Stocks Edge Higher; NY Empire State Manufacturing Index Falls In July
Lisa Levin - Jul 17, 2023, 10:01AM
Cantor Fitzgerald Reiterates Overweight on Acumen Pharmaceuticals, Maintains $13 Price Target
Benzinga Newsdesk - Jul 17, 2023, 9:51AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Jul 17, 2023, 9:06AM
Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 17, 2023, 8:45AM
Market-Moving News for July 17th
Benzinga Newsdesk - Jul 17, 2023, 8:41AM
Acumen Pharma's Stock Doubles In One Session - Here's Why
Vandana Singh - Jul 17, 2023, 8:41AM
Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Lisa Levin - Jul 17, 2023, 7:27AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Jul 17, 2023, 6:19AM
Acumen Pharmaceuticals shares are trading higher after the company presented topline results from Phase 1 study of ACU193 for early Alzheimer's disease at the Alzheimer's Association International Conference 2023.
Benzinga Newsdesk - Jul 17, 2023, 4:53AM
Sunday, Acumen Presented Topline Results From Phase 1 Study Of ACU193 For Early Alzheimer's Disease; The Trial Met Primary And Secondary Objectives
Benzinga Newsdesk - Jul 17, 2023, 4:52AM

Tuesday, July 11, 2023

Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Jul 11, 2023, 1:26PM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights - Jul 11, 2023, 9:12AM
Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 11, 2023, 8:33AM

Tuesday, June 13, 2023

12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Jun 13, 2023, 1:31PM
Acumen Pharmaceuticals shares are trading higher after the company announced it will present topline results from a Phase 1 trial of its candidate ACI193 at the Alzheimer's Association International Conference in July.
Benzinga Newsdesk - Jun 13, 2023, 11:33AM
Acumen Pharmaceuticals To Present Topline Results From First-in-human Phase 1 Study Of ACU193 For Early Alzheimer's Disease During Featured Research Session At The Alzheimer's Association International Conference 2023 On 16 July
Benzinga Newsdesk - Jun 13, 2023, 7:10AM

Thursday, June 08, 2023

Director at Acumen Pharmaceuticals Acquires Company Stock Options Worth 25,000 Shares
Benzinga Insights - Jun 8, 2023, 11:02AM
Board Member at Acumen Pharmaceuticals Acquires Company Stock Options Worth 25,000 Shares
Benzinga Insights - Jun 8, 2023, 11:02AM
Acumen Pharmaceuticals Board Member Awarded $123K Worth of Stock Options
Benzinga Insights - Jun 8, 2023, 11:02AM

Thursday, May 18, 2023

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Benzinga Insights - May 18, 2023, 11:00AM
Cantor Fitzgerald Initiates Coverage On Acumen Pharmaceuticals with Overweight Rating, Announces Price Target of $13
Benzinga Newsdesk - May 18, 2023, 8:52AM

Wednesday, May 10, 2023

Top 5 Health Care Stocks That May Collapse In Q2
Lisa Levin - May 10, 2023, 7:53AM

Tuesday, May 09, 2023

Acumen Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 EPS results.
Benzinga Newsdesk - May 9, 2023, 1:22PM
Acumen Pharmaceuticals Q1 EPS $(0.28) Beats $(0.35) Estimate
Benzinga Newsdesk - May 9, 2023, 7:05AM
Earnings Scheduled For May 9, 2023
Benzinga Insights - May 9, 2023, 6:03AM

Monday, May 08, 2023

Earnings Outlook For Acumen Pharmaceuticals
Benzinga Insights - May 8, 2023, 4:01PM

Tuesday, March 28, 2023

Credit Suisse Maintains Outperform on Acumen Pharmaceuticals, Lowers Price Target to $13
Benzinga Newsdesk - Mar 28, 2023, 7:11AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Mar 28, 2023, 6:38AM

1
2
3
4
5
6
7
Next
17

Latest News for Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

Acumen Pharmaceuticals Stock (NASDAQ: ABOS)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, September 06, 2023

Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
David Willey - Sponsored

Wednesday, August 09, 2023

Credit Suisse Reiterates Outperform on Acumen Pharmaceuticals, Maintains $13 Price Target
Benzinga Newsdesk - Aug 9, 2023, 9:02AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Aug 9, 2023, 6:30AM

Tuesday, August 08, 2023

Acumen Pharmaceuticals Q2 EPS $(0.28) Beats $(0.36) Estimate
Benzinga Newsdesk - Aug 8, 2023, 7:02AM
Earnings Scheduled For August 8, 2023
Benzinga Insights - Aug 8, 2023, 4:48AM

Monday, August 07, 2023

Acumen Pharmaceuticals's Earnings: A Preview
Benzinga Insights - Aug 7, 2023, 5:01PM

Wednesday, July 26, 2023

Director At This Health Care Company Buys $40.00M of Stock
Benzinga Insights - Jul 26, 2023, 11:02AM
$40M Bet On Acumen Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
Lisa Levin - Jul 26, 2023, 8:50AM
Neuroinflammation A Key Indicator For Alzheimer's, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
David Willey - Sponsored

Thursday, July 20, 2023

B of A Securities Reinstates Buy on Acumen Pharmaceuticals, Announces $14 Price Target
Benzinga Newsdesk - Jul 20, 2023, 6:52AM

Wednesday, July 19, 2023

Acumen Pharmaceuticals Upsizes Its Previously Announced Offering To $130M From $100M, Pricing 16,774,193 Shares Offering At $7.75/Share
Benzinga Newsdesk - Jul 19, 2023, 1:09AM

Tuesday, July 18, 2023

Acumen Pharmaceuticals shares are trading lower after the company announced a $100 million underwritten public offering.
Benzinga Newsdesk - Jul 18, 2023, 3:21PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Jul 18, 2023, 1:31PM
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Jul 18, 2023, 1:00PM
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 18, 2023, 8:12AM
Masimo, Acumen Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Lisa Levin - Jul 18, 2023, 6:46AM

Monday, July 17, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Jul 17, 2023, 5:32PM
Acumen Pharmaceuticals Commence Public Offering Of $100M Of Shares Of Its Common Stock
Benzinga Newsdesk - Jul 17, 2023, 4:55PM
Acumen Pharmaceuticals Plans To File A Preliminary Prospectus Supplement With The SEC For A Proposed Offering Of Common Stock, And As Of June 30, 2023, The Company Had Approximately $172.2M In Cash And Marketable Securities
Happy Mohamed - Jul 17, 2023, 4:50PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Jul 17, 2023, 1:31PM
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Jul 17, 2023, 1:14PM
Ford Motor Cuts Prices For F-150 Lightning Truck, Microsoft-Sony Sign Agreement for 'Call of Duty,' Alibaba Stock Slips on China's Q2 GDP Sentiment: Today's Top Stories
Vandana Singh - Jul 17, 2023, 10:13AM
US Stocks Edge Higher; NY Empire State Manufacturing Index Falls In July
Lisa Levin - Jul 17, 2023, 10:01AM
Cantor Fitzgerald Reiterates Overweight on Acumen Pharmaceuticals, Maintains $13 Price Target
Benzinga Newsdesk - Jul 17, 2023, 9:51AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Jul 17, 2023, 9:06AM
Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 17, 2023, 8:45AM
Market-Moving News for July 17th
Benzinga Newsdesk - Jul 17, 2023, 8:41AM
Acumen Pharma's Stock Doubles In One Session - Here's Why
Vandana Singh - Jul 17, 2023, 8:41AM
Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Lisa Levin - Jul 17, 2023, 7:27AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Jul 17, 2023, 6:19AM
Acumen Pharmaceuticals shares are trading higher after the company presented topline results from Phase 1 study of ACU193 for early Alzheimer's disease at the Alzheimer's Association International Conference 2023.
Benzinga Newsdesk - Jul 17, 2023, 4:53AM
Sunday, Acumen Presented Topline Results From Phase 1 Study Of ACU193 For Early Alzheimer's Disease; The Trial Met Primary And Secondary Objectives
Benzinga Newsdesk - Jul 17, 2023, 4:52AM

Tuesday, July 11, 2023

Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Jul 11, 2023, 1:26PM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights - Jul 11, 2023, 9:12AM
Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jul 11, 2023, 8:33AM

Tuesday, June 13, 2023

12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Jun 13, 2023, 1:31PM
Acumen Pharmaceuticals shares are trading higher after the company announced it will present topline results from a Phase 1 trial of its candidate ACI193 at the Alzheimer's Association International Conference in July.
Benzinga Newsdesk - Jun 13, 2023, 11:33AM
Acumen Pharmaceuticals To Present Topline Results From First-in-human Phase 1 Study Of ACU193 For Early Alzheimer's Disease During Featured Research Session At The Alzheimer's Association International Conference 2023 On 16 July
Benzinga Newsdesk - Jun 13, 2023, 7:10AM

Thursday, June 08, 2023

Director at Acumen Pharmaceuticals Acquires Company Stock Options Worth 25,000 Shares
Benzinga Insights - Jun 8, 2023, 11:02AM
Board Member at Acumen Pharmaceuticals Acquires Company Stock Options Worth 25,000 Shares
Benzinga Insights - Jun 8, 2023, 11:02AM
Acumen Pharmaceuticals Board Member Awarded $123K Worth of Stock Options
Benzinga Insights - Jun 8, 2023, 11:02AM

Thursday, May 18, 2023

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Benzinga Insights - May 18, 2023, 11:00AM
Cantor Fitzgerald Initiates Coverage On Acumen Pharmaceuticals with Overweight Rating, Announces Price Target of $13
Benzinga Newsdesk - May 18, 2023, 8:52AM

Wednesday, May 10, 2023

Top 5 Health Care Stocks That May Collapse In Q2
Lisa Levin - May 10, 2023, 7:53AM

Tuesday, May 09, 2023

Acumen Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 EPS results.
Benzinga Newsdesk - May 9, 2023, 1:22PM
Acumen Pharmaceuticals Q1 EPS $(0.28) Beats $(0.35) Estimate
Benzinga Newsdesk - May 9, 2023, 7:05AM
Earnings Scheduled For May 9, 2023
Benzinga Insights - May 9, 2023, 6:03AM

Monday, May 08, 2023

Earnings Outlook For Acumen Pharmaceuticals
Benzinga Insights - May 8, 2023, 4:01PM

Tuesday, March 28, 2023

Credit Suisse Maintains Outperform on Acumen Pharmaceuticals, Lowers Price Target to $13
Benzinga Newsdesk - Mar 28, 2023, 7:11AM
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk - Mar 28, 2023, 6:38AM

1
2
3
4
5
6
7
Next
17

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2023 Benzinga | All Rights Reserved